Shoulder and Hip Stiffness With Systemic Symptoms

An adult older than 50 reports six weeks of bilateral shoulder aching, hip-girdle stiffness lasting more than an hour each morning, fatigue, and unintentional weight loss. Rising from a chair and dressing are difficult, yet formal strength is preserved once pain is overcome. Erythrocyte sedimentation rate and C-reactive protein are elevated. The pattern suggests polymyalgia rheumatica, but constitutional symptoms also widen the search to vasculitis, infection, malignancy, endocrine disease, and late-onset inflammatory arthritis.

Case focus#

The crucial decision is whether any cranial or visual feature makes associated giant cell arteritis an emergency requiring immediate treatment and vascular confirmation, while the broader stiffness syndrome is evaluated without using a glucocorticoid response as a stand-alone diagnostic test. The competing risks are preventable visual loss, treatment toxicity, and masking a mimic.

This analysis concentrates on calibration. It compares plausible explanations, asks which observations genuinely discriminate among them, and keeps the working diagnosis open to revision as new evidence arrives.

Problem representation#

The useful representation is not a label alone. It combines the tempo of the problem, the setting, the physiologic or functional threat, the evidence already available, and the important information that is still missing. For this polymyalgia rheumatica and giant cell arteritis analysis, the working frame must remain broad enough to compare Polymyalgia rheumatica, Giant cell arteritis, Late-onset rheumatoid arthritis, Inflammatory or toxic myopathy without allowing a familiar first impression to become an untested conclusion.

The setting materially changes the plan: An ambulatory service with same-day inflammatory markers, focused vascular examination, musculoskeletal ultrasound, and rapid access to ophthalmology or rheumatology pathways.. Available monitoring, access to consultation, travel time, record continuity, and the reliability of follow-through alter what counts as a safe next step. A plan that is reasonable in a continuously monitored environment may be unsafe when results return after discharge or urgent reassessment is difficult.

Immediate safety priorities#

• New visual disturbance: Transient or persistent monocular loss, diplopia, or visual blurring can signal ischemic giant cell arteritis and requires immediate action to protect remaining vision.
• Cranial ischemic symptoms: New localized headache, scalp tenderness, jaw or tongue claudication, and abnormal temporal arteries materially increase concern for giant cell arteritis.
• Objective muscle weakness: True proximal weakness, dysphagia, dark urine, or marked creatine kinase elevation points away from uncomplicated polymyalgia toward myositis, neuropathy, or toxic myopathy.
• Persistent constitutional decline: Ongoing fever, night sweats, weight loss, adenopathy, or cytopenias despite appropriate initial management requires renewed investigation for infection, malignancy, or systemic inflammation.

These findings guide how quickly to stabilize, consult, and escalate care. They do not establish a diagnosis; the causal assessment continues alongside the immediate response.

Prioritized differential diagnosis#

Polymyalgia rheumatica#

What supports it. Age above 50, abrupt bilateral shoulder symptoms, prolonged morning stiffness, hip involvement, preserved strength, and elevated inflammatory markers form a coherent pattern.

What argues against it or keeps uncertainty open. Prominent peripheral synovitis, normal inflammatory markers with strongly atypical features, objective weakness, or poor sustained response should weaken confidence.

Discriminating next step. Exclude key mimics, document baseline function and inflammation, then judge a cautious treatment trial by clinical trajectory rather than response alone.

Giant cell arteritis#

What supports it. New headache, scalp tenderness, jaw claudication, visual symptoms, thrombocytosis, or large-vessel features can accompany the stiffness syndrome.

What argues against it or keeps uncertainty open. Absence of cranial symptoms lowers probability but does not exclude extracranial large-vessel disease or future evolution.

Discriminating next step. When suspected, begin the urgent pathway and arrange temporal artery ultrasound, biopsy, or vascular imaging without allowing confirmation logistics to delay vision-preserving treatment.

Late-onset rheumatoid arthritis#

What supports it. Symmetric small-joint swelling, peripheral synovitis, rheumatoid factor or anti-CCP antibodies, and a less complete proximal response favor rheumatoid arthritis.

What argues against it or keeps uncertainty open. Pure girdle pain without synovitis or serologic support and rapid durable resolution at low treatment intensity makes it less likely.

Discriminating next step. Examine hands, wrists, knees, and feet carefully, obtain selective serology, and use ultrasound when occult synovitis would alter long-term therapy.

Inflammatory or toxic myopathy#

What supports it. Objective weakness, dysphagia, rash, dark urine, medicine triggers, or elevated muscle enzymes supports muscle disease rather than pain-limited movement.

What argues against it or keeps uncertainty open. Normal power after encouragement and normal creatine kinase argue against many myopathies, although they do not exclude every subtype.

Discriminating next step. Check medicine history, creatine kinase, thyroid testing, and focused neuromuscular findings, then pursue electromyography or imaging only if the signal persists.

Infection, malignancy, or endocrine mimic#

What supports it. Night sweats, focal pain, adenopathy, anemia, abnormal protein studies, fever, thyroid symptoms, or exposure history can reproduce constitutional and musculoskeletal complaints.

What argues against it or keeps uncertainty open. A classic symmetric syndrome with normal directed screening and sustained improvement makes these alternatives less likely but never impossible.

Discriminating next step. Let specific history, examination, blood count, chemistry, thyroid testing, protein studies, and age-appropriate investigations guide further work rather than ordering indiscriminate panels.

Keep the ranked differential open to revision. Consider probability, the consequences of delay, reversibility, and the burden of testing together. A dangerous alternative may need early exclusion even when it is not the most likely explanation.

Evidence-gathering strategy#

• Separate pain-limited movement from weakness. Observed rising, shoulder abduction, neck flexion, reflexes, and gait distinguish stiffness from primary neuromuscular loss. Interpretation: Preserved force supports polymyalgia, while objective weakness redirects testing toward muscle or neurologic disease.
• Ask directly about giant cell arteritis. Visual disturbance, jaw claudication, localized headache, scalp pain, limb claudication, and aortic symptoms may not be volunteered during a stiffness visit. Interpretation: Any credible ischemic feature changes the problem from routine diagnosis to urgent vascular assessment and treatment.
• Measure inflammation and important mimics. ESR, CRP, blood count, chemistry, alkaline phosphatase, creatine kinase, thyroid testing, and selective serology establish a baseline and identify competing mechanisms. Interpretation: Inflammation supports but does not prove polymyalgia; discordant cytopenias, muscle injury, or endocrine results reorder the differential.
• Examine peripheral joints and arteries. Synovitis, bruits, pulse asymmetry, temporal artery change, and blood-pressure differences expose rheumatoid or large-vessel alternatives. Interpretation: Peripheral synovitis raises inflammatory arthritis, while vascular abnormalities justify targeted imaging beyond cranial arteries.
• Track function and steroid toxicity. Dressing, chair rise, sleep, pain, inflammatory markers, glucose, pressure, mood, infection, and bone risk show both benefit and harm over time. Interpretation: Clinical relapse with dose reduction differs from isolated marker fluctuation; persistent symptoms despite treatment demand diagnostic reassessment.

Choose tests that can change a decision. Interpret results in light of timing, pretest probability, measurement limitations, and recent treatment. A reassuring result may have been obtained too early or under conditions that limit its meaning.

Progressive course and interpretation#

Direct questioning uncovers intermittent scalp tenderness but no visual symptom or jaw claudication. Because this is a cranial symptom in an adult older than 50 with systemic inflammation, the team activates a same-day giant cell arteritis pathway rather than treating the presentation as routine polymyalgia. Treatment appropriate to the assessed ischemic risk begins while temporal artery ultrasound and confirmatory evaluation proceed without delay. Repeated vascular assessment does not support cranial or large-vessel arteritis. When proximal symptoms improve but inflammatory markers and night sweats persist, a repeated examination identifies peripheral synovitis, moving late-onset rheumatoid arthritis above uncomplicated polymyalgia rheumatica and prompting revision of the treatment plan.

Changes over time provide further evidence. Improvement after treatment can support a mechanism without proving it. If treatment does not help, reconsider the diagnosis, how and when it was delivered, adherence, and competing pathology. Explain conflicting findings rather than averaging them away.

Management reasoning#

• Protect vision when arteritis is plausible. Treatment and urgent confirmation should proceed on a time-sensitive pathway because ischemic visual injury can become irreversible.
• Use the lowest effective anti-inflammatory intensity. A planned taper anchored to symptoms and function limits cumulative glucocorticoid harm while allowing relapse to be recognized.
• Prevent treatment complications. Assess vaccination, infection risk, bone protection, glucose, blood pressure, eye health, gastrointestinal risk, and drug interactions before problems emerge.
• Reopen an atypical course. Poor response, recurring constitutional symptoms, objective weakness, or new synovitis should prompt investigation of mimics rather than indefinite dose escalation.
• Coordinate longitudinal ownership. One clinician or team should own taper decisions, laboratory trends, toxicity surveillance, and rapid access for possible giant cell arteritis symptoms.

Match management to severity and uncertainty. Specify monitoring targets, foreseeable adverse effects, and when to stop or escalate care. Drug choice, doses, and procedures depend on verified individual factors, current local protocols, contraindications, and the responsible treating team. The focus here is the reasoning behind those decisions and their safeguards.

Communication and shared decisions#

Explain that the symptom pattern is compatible with polymyalgia rheumatica but is not uniquely diagnostic, and that new visual disturbance, jaw fatigue while chewing, or a new localized headache changes urgency immediately. Discuss the expected benefits and harms of glucocorticoids, bone and metabolic protection, and why response and laboratory trends must be interpreted together.

Explain what is known and uncertain, why the next step is recommended, the alternatives, and which changes require urgent reassessment. Use teach-back, qualified interpretation when needed, and accessible formats. Assign responsibility for pending results so the discussion leads to a safer plan.

Continuity and safety net#

• Treat any new visual loss, diplopia, jaw claudication, or severe new localized headache as an urgent same-day event.
• Report fever, focal infection symptoms, black stools, severe mood change, marked thirst, or other possible glucocorticoid complications promptly.
• Arrange diagnostic review if stiffness does not improve as expected, true weakness appears, peripheral joints swell, or weight loss continues.
• Do not alter or stop long-term glucocorticoids abruptly without a coordinated plan because withdrawal and disease relapse require different responses.

Confirm follow-through. Record who will receive each pending result, when reassessment should happen, what to do if contact fails, and which clinical or functional outcome will show whether the plan is working.

Equity and systems analysis#

Morning disability may make transport, dressing, phlebotomy, and medication organization difficult even when the person lives independently. Visual or hearing impairment can make written warnings ineffective. Offer accessible instructions, coordinate clustered visits, account for medication costs, and do not assume that a caregiver is available to monitor new cranial symptoms or steroid adverse effects.

Consider how transportation, medication cost, work schedules, caregiving, health literacy, language, disability access, digital connectivity, and prior experiences of care affect the presentation and the feasibility of the plan. Addressing these constraints supports both accurate diagnosis and fair care.

Reasoning capabilities demonstrated#

• Distinguishes pain-limited function from objective proximal weakness through direct observation and examination.
• Screens a polymyalgia pattern for associated giant cell arteritis before treating it as routine musculoskeletal disease.
• Interprets steroid response as supportive trajectory evidence rather than diagnostic proof.
• Uses discordant symptoms, markers, and examination findings to uncover inflammatory arthritis or systemic mimics.
• Balances disease control against cumulative glucocorticoid harm through explicit monitoring and ownership.

Key takeaways#

• Shoulder and hip stiffness with preserved strength supports polymyalgia rheumatica, but infection, cancer, myopathy, endocrine disease, and inflammatory arthritis remain important mimics.
• Visual symptoms or cranial ischemic features can transform the visit into a giant cell arteritis emergency.
• A brisk glucocorticoid response raises confidence but cannot rescue an atypical course from further diagnostic scrutiny.